Latest & greatest articles for Galantamine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Galantamine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Galantamine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Galantamine

21. Galantamine for Alzheimer's disease. (PubMed)

Galantamine for Alzheimer's disease. Galantamine (also called galanthamine, marketed as Reminyl (Janssen)) was isolated from several plants, including daffodil bulbs, but is now synthesized. Galantamine is a specific, competitive, and reversible acetylcholinesterase inhibitor. It is also an allosteric modulator at nicotinic cholinergic receptor sites potentiating cholinergic nicotinic neurotransmission. A small number of early studies showed mild cognitive and global benefits for patients (...) with Alzheimer's disease (AD), and recently several multicenter clinical trials have been published with positive findings. Galantamine has received regulatory approval in 29 counties: Argentina, Australia, Canada, Czechia, the European Union (except for The Netherlands), Iceland, Korea, Mexico, Norway, Poland, Singapore, South Africa, Switzerland, Thailand, and the United States.The objective of this overview is to assess the clinical effects of galantamine in patients with probable AD, and to investigate

2001 Cochrane

22. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease

Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation National Institute for Clinical Excellence. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 19. 2001 Authors' objectives To provide guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. Authors' conclusions Guidance 1.1 The three drugs donepezil, rivastigmine

2001 Health Technology Assessment (HTA) Database.

23. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review

Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review. Health Technology Assessment 2001; 5(1): 1-137 Authors' objectives To provide a rapid and systematic review of the clinical

2001 Health Technology Assessment (HTA) Database.

24. Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada

Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada Getsios D, Caro J J, Caro G, Ishak K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of galantamine, a cholinesterase inhibitor, to restore cognitive ability or to slow cognitive deterioration in patients with Alzheimer's disease (AD). Galantamine also has a modulating effect on nicotinic receptors. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients

2001 NHS Economic Evaluation Database.

25. Clinical and cost-effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review

Clinical and cost-effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review Clinical and cost-effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review Clinical and cost-effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N Authors' objectives To provide a rapid (...) and systematic review of the clinical effectiveness and cost-effectiveness of donepezil, rivastigmine and galantamine in the symptomatic treatment of people suffering from Alzheimer's disease (AD). Searching The following databases were searched from their inception to March to July, 2000: MEDLINE, EMBASE, the Cochrane Library, DARE, NHS EED, the National Researh Register, the Science Citation Index, BIOSIS Previews, EconLit, the MRC Clinical Trials Directory, an Early Warning System database, Current

2001 DARE.

26. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. (PubMed)

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. To evaluate the efficacy and safety of galantamine in the treatment of Alzheimer's disease.Randomised, double blind, parallel group, placebo controlled trial.86 outpatient clinics in Europe and Canada.653 patients with mild to moderate Alzheimer's disease.Patients randomly assigned to galantamine had their daily dose (...) escalated over three to four weeks to maintenance doses of 24 or 32 mg.Scores on the 11 item cognitive subscale of the Alzheimer's disease assessment scale, the clinician's interview based impression of change plus caregiver input, and the disability assessment for dementia scale. The effect of apolipoprotein E4 genotype on reponse to treatment was also assessed.At six months, patients who received galantamine had a significantly better outcome on the 11 item cognitive subscale of the Alzheimer's

Full Text available with Trip Pro

2000 BMJ